Chronic NMDA receptor stimulation: therapeutic implications of its effect on adenosine A1 receptors

Eur J Pharmacol. 1995 Sep 5;283(1-3):185-92. doi: 10.1016/0014-2999(95)00338-l.

Abstract

It is known that stimulation of adenosine A1 receptors has a modulatory effect on the excitability of postsynaptic NMDA receptors. Conversely, acute stimulation of NMDA receptors results in release of adenosine via calcium-independent mechanisms. These findings indicate a close functional relationship between these receptors. It is, therefore, possible that chronic, low level stimulation of the NMDA receptor may have a negative impact on these modulatory processes. To investigate this possibility, we have subjected C57BL mice either to an acute injection of a N6-cyclopentyladenosine (CPA, 0.01 mg/kg) or deoxycoformycin (1 mg/kg) followed by a convulsant dose of N-methyl-D-aspartate (NMDA) (60 mg/kg) or to chronic, low level (20 mg/kg i.p. daily) exposure to NMDA for 8 weeks. One day after the last injection of NMDA, animals were injected either with a convulsant dose of NMDA alone, or with either CPA at 0.001 or 0.01 mg/kg, or with 1 mg/kg deoxycoformycin followed 15 min later by 60 mg/kg NMDA. Neither CPA nor deoxycoformycin were protective when NMDA was given acutely at 60 mg/kg. Chronic treatment with NMDA alone or chronic administration of NMDA followed by 0.001 mg/kg CPA had no significant effect on mortality following a convulsant dose of NMDA. However, when the chronic regimen of NMDA was followed by either 0.01 mg/kg CPA or 1 mg/kg deoxycoformycin, mortality was reduced to 10% (CPA), or eliminated completely (deoxycoformycin). Moreover, combination of chronic NMDA treatment with either CPA (both doses) or deoxycoformycin produced a significant improvement in other measures, i.e., seizure onset, intensity of neurological impairment, and extension of time to death.(ABSTRACT TRUNCATED AT 250 WORDS)

MeSH terms

  • Adenosine / analogs & derivatives
  • Adenosine / pharmacology
  • Animals
  • Cerebral Cortex / metabolism
  • Hippocampus / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • N-Methylaspartate / pharmacology*
  • Pentostatin / pharmacology
  • Polymerase Chain Reaction
  • Receptors, N-Methyl-D-Aspartate / drug effects*
  • Receptors, Purinergic P1 / drug effects*
  • Seizures

Substances

  • Receptors, N-Methyl-D-Aspartate
  • Receptors, Purinergic P1
  • Pentostatin
  • N(6)-cyclopentyladenosine
  • N-Methylaspartate
  • Adenosine